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This review describes the structure-based reverse vaccinology approach aimed at devel-
oping vaccine immunogens capable of inducing antibodies that broadly neutralize HIV-1.
Some basic principles of protein immunochemistry are reviewed and the implications of the
extensive polyspeciﬁcity of antibodies for vaccine development are underlined. Although it
is natural for investigators to want to know the cause of an effective immunological inter-
vention, the classic notion of causality is shown to have little explanatory value for a system
as complex as the immune system, where any observed effect always results from many
interactions between a large number of components. Causal explanations are reductive
because a single factor is singled out for attention and given undue explanatory weight
on its own. Other examples of the negative impact of reductionist thinking on HIV vac-
cine development are discussed. These include (1) the failure to distinguish between the
chemical nature of antigenicity and the biological nature of immunogenicity, (2) the belief
that when an HIV-1 epitope is reconstructed by rational design to better ﬁt a neutralizing
monoclonal antibody (nMab), this will produce an immunogen able to elicit Abs with the
same neutralizing capacity as theAb used as template for designing the antigen, and (3) the
belief that protection against infection can be analyzed at the level of individual molecular
interactions although it has meaning only at the level of an entire organism. The numer-
ous unsuccessful strategies that have been used to design HIV-1 vaccine immunogens
are described and it is suggested that the convergence of so many negative experimental
results justiﬁes the conclusion that reverse vaccinology is unlikely to lead to the devel-
opment of a preventive HIV-1 vaccine. Immune correlates of protection in vaccines have
not yet been identiﬁed because this will become feasible only retrospectively once an
effective vaccine exists. The ﬁnding that extensive antibody afﬁnity maturation is needed
to obtain mature anti-HIV-1 Abs endowed with a broad neutralizing capacity explains why
antigens designed to ﬁt matured Mabs are not effective vaccine immunogens since these
are administered to naive recipients who possess only B-cell receptors corresponding to
the germline version of the matured Abs.
Keywords: antibody affinity maturation, antibody polyspecificity, discontinuous protein epitopes, HIV vaccines,
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INTRODUCTION
Before it was recognized that the vast majority of epitopes in
proteins are discontinuous, i.e., composed of surface residues
originating from distant parts of the protein sequence, short
peptide segments of viral proteins able to react with antiprotein
antibodies were considered to be continuous epitopes mimick-
ing the antigenicity of the protein. This led to the expectation
that if such peptides could be made to adopt the 3D structure
observed when the corresponding regions of the viral protein are
bound to neutralizing monoclonal antibodies (nMabs), the pep-
tides would be able to act as effective vaccine immunogens. More
than a thousand peptides were tested over the years as poten-
tial synthetic peptide vaccines against a variety of pathogens but
not a single peptide passed phase III clinical trials nor was mar-
keted for use in humans (Hans et al., 2006). These attempts to
develop synthetic peptide vaccines were based on the premise
that continuous epitopes reacting with antibodies speciﬁc for
a viral protein may be able to induce antibodies that recog-
nized the virus and neutralized its infectivity. It was usually
found, however, that few continuous epitopes of viral proteins
were able to elicit antibodies that recognized the native protein
although most of them readily induced antibodies that reacted
with the peptide immunogen (Van Regenmortel and Muller, 1999;
Van Regenmortel, 2009a).
In order to be useful as a vaccine immunogen, a peptide
must not only induce antipeptide antibodies but must also
possess so-called cross-reactive immunogenicity, i.e., the abil-
ity to induce antibodies that recognize the cognate protein,
as well as cross-protective immunogenicity, i.e., the ability to
induce antibodies that neutralize the infectivity of the pathogen
(Van Regenmortel, 2006). Since very few linear peptides were
found to possess the required cross-reactive and cross-protective
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immunogenicity, it became generally accepted that the prospects
of developing effective synthetic peptide vaccines were very poor.
In the present review, it will be argued that many of the imped-
iments that prevented the development of synthetic peptide
vaccines in the past are responsible for the lack of success observed
in current attempts to design HIV-1 vaccines based on the 3D
structure of more complex discontinuous epitopes.
Arguments will be presented that the failure to develop an
HIV-1 vaccine by rational design is mainly due to the underly-
ing reductionist thinking that pervades much basic research in
immunology and vaccinology. A reductionist mindset obscures
the fundamental divide between antigenicity and immunogenicity,
i.e., between the chemical nature of antigen–antibody recognition
processes and the biological nature of the immunogenic processes
that allow a viral antigen to give rise to a protective immune
response in a competent host.
ANTIBODY POLYSPECIFICITY AND THE RELATIONAL
NATURE OF EPITOPES AND PARATOPES
The regions of antigen molecules recognized by antibodies are
called epitopes while the regions of antibodies that bind to epi-
topes are called paratopes. Both regions are usually identiﬁed by
solving the 3D structure of antigen–antibody complexes anddeter-
mining which amino acids in the two partners make contact with
each other (Sundberg and Mariuzza, 2002). When a paratope is
deﬁned solely in terms of residues that make contact with an epi-
tope, it is difﬁcult to account for the observation that the binding
activity of an antibody often depends on structural features distant
from the paratope itself (Schildbach et al., 1993; Chatellier et al.,
1996). Similarly, residues in the antigen that are not in contact
with the antibody may be able to affect the binding process, for
instance by inﬂuencing the conformation or stability of the free
form of the protein or by participating in long-range allosteric
effects. Complex formation is driven by the free energy change
associated with the binding process, and residues away from the
contact regions are often able to contribute to this free energy
change as demonstrated by the changes in afﬁnity and speciﬁcity
that result when these residues are mutated (Greenspan and Di
Cera, 1999). Mutational studies have also shown that not all con-
tact residues contribute to the interaction energy, conﬁrming that
epitopes deﬁned structurally differ from epitopes identiﬁed in
functional assays (Cunningham and Wells, 1993). Furthermore,
the structures visualized in antigen–antibody complexes may dif-
fer from the structures of the binding sites in the free molecules,
before the processes of mutual adaptation and induced ﬁt that
often occur when the two partners interact (Wilson and Stanﬁeld,
1994; Bosshard, 2001; Kim et al., 2011). As a result the structure of
an epitope bound to an nMab may not correspond to the structure
that is recognized by B-cell receptors (BCRs) during the immu-
nization process and is presumed to be required in a vaccine. It
is also known that residues in the antigen that are not in contact
with paratope residues may be able to modulate the immunogenic
activity of epitopes (Moudgil et al., 1998). Itwas also found that the
sensitivity to neutralization of HIV-1 strains that harbor the core
epitope recognized by nMab 4E10 was modulated by amino acid
substitutions elsewhere in the viral envelope (Gray et al., 2008).
All these observations are consistent with the view that epitopes
and paratopes are fuzzy binding sites devoid of clear-cut structural
boundaries (Van Regenmortel, 1998a).
Speciﬁcity has been deﬁned by Medawar and Medawar (1978)
as the complementary relationship existing between an agent and
something acted on,which arises from the stereochemical comple-
mentarity found between such partners as antigen and antibody,
enzyme and substrate, or receptor and ligand. In addition to being
deﬁned as a measure of goodness of ﬁt between paratope and
epitope, antibody speciﬁcity can also be viewed as resulting from
the capacity of an antibody to discriminate between two or more
antigens (Day, 1990, p. 291; Frank, 2002, p. 42).
Antibodies recognize complementary antigens through the
extremely versatile binding sites of immunoglobulin (Ig)
molecules which are able to recognize virtually every molecular
structure (Nezlin, 1994; Wucherpfennig et al., 2007). The Ig bind-
ing site consists of 50–70 hypervariable residues distributed over
the six complementarity determining regions (CDRs) of the vari-
able domains of the heavy and light Ig chains. Each Ig binding site
contains numerous overlapping and non-overlapping paratope
subsites of 10–20 residues, each approximately 2800 A2 in area,
that are able to bind to different antigens. The surface of one
paratope corresponds to only 20–35% of the total surface encom-
passed by the CDRs of an Igmolecule (Denisova et al., 2010). An Ig
molecule may sometimes harbor two non-overlapping paratopes,
which will allow it to bind simultaneously to two small anti-
gens (Richards et al., 1975; Bhattacharjee and Glaudemans, 1978;
Eisen and Chakraborty, 2010). A more common situation is that
paratope subsites present in an Ig molecule at least partly overlap
which prevents two different antigens from binding simultane-
ously to the same Ig. The presence of multiple paratopes in Ig
molecules means that antibody molecules are always polyspeciﬁc
(Frank, 2002).
The polyspeciﬁcity of antibodies is also demonstrated by their
ability to bind large numbers of small peptides possessing lim-
ited sequence similarity and by the fact that many residues of
an epitope can be replaced by any other amino acid without
impairing the epitope’s antigenic reactivity (Getzoff et al., 1988;
Geysen et al., 1988). When peptide libraries are tested for their
ability to bind Mabs raised against a protein, it is usually found
that many peptides that bind Ig residues situated outside the
paratope region show little sequence similarity with the target
antigen. Such peptides are therefore poor mimics of any epi-
tope of the native protein although they are often referred to as
mimotopes (Van Regenmortel, 2009a; Denisova et al., 2010; Irving
et al., 2001, 2010).
The fact that every antibodymolecule always harbors numerous
paratopes, allowing it to bind many related or unrelated epitopes,
was recognized as soon as myeloma proteins and Mabs became
available and their speciﬁcity could be analyzed (for a review, see
Eisen and Chakraborty, 2010). It is therefore astonishing that the
implications of antibody polyspeciﬁcity for vaccine development
were pointed out only recently (Van Regenmortel, 2011a, 2012)
since the degeneracy of the immune system has been known for
many years (Sperling et al., 1983; Parnes, 2004; Wucherpfennig
et al., 2007).
The entire surface of proteins harbors a large number of
overlapping discontinuous epitopes which can be identiﬁed only
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when many Mabs reacting with the protein have been isolated.
Discontinuous epitopes consist of two to ﬁve short linear stretches
of residues that are distant in the protein sequence but are brought
together by the folding of the peptide chain. Since the number of
Mabs available for each protein is usually limited, it may seem
that antigenicity is located in discrete epitope regions rather than
forming an antigenic continuum at the surface of the protein (Van
Regenmortel, 2009b). Since discontinuous epitopes cannot be iso-
lated in active form from the protein in which they are embedded,
it is impossible to study their capacity to act as effective vaccine
immunogens on their own. The intact, native protein must always
be used as immunogen and this inevitably produces a hetero-
geneous response against the numerous epitopes present in the
protein (Van Regenmortel, 2012).
A second type of protein epitope called a continuous epitope
is deﬁned as any linear peptide region of the protein, usually
5–8 residues long, that is able to cross-react with antibodies raised
against the protein. Continuous epitopes usually do not exist as
individual, discrete binding or immunogenic sites in the native
protein, and only some of their residues may be present at the
surface of the protein where they are usually part of discontinuous
epitopes (Chen et al., 2009).
The same residues at the surface of a protein may contribute to
several overlappingdiscontinuous epitopes recognized bydifferent
antibodies that present no similarity in their CDRs. As illustrated
in Figure 1 for two lysozyme antibodies, two Mabs recognizing
what appears to be a very similar epitope may bind through com-
pletely different paratopes that show no similarity in chemical
bonding pattern. Epitopes and paratopes are in fact relational
entities that can be deﬁned only by their mutual complemen-
tarity since they depend on each other to acquire a recognizable
identity. Epitopes and paratopes are thus not intrinsic structural
features of antigens and antibodies, respectively, because they do
not exist as speciﬁc sites in the absence of a complementarity nexus
between two partners (Van Regenmortel, 2009b). This means, for
instance, that the two paratopes illustrated in Figure 1 do not actu-
ally recognize the same epitope. In view of the relational nature
of epitopes, the number of epitopes in a protein is equal to the
number of different Mabs that can be raised against it. This num-
ber was found to be 115 for the insulin molecule (Schroer et al.,
1983) and more than a thousand for the BLyS molecule (Edwards
et al., 1993). Another consequence of this relational nexus is that
analyzing the antigenicity of a protein is equivalent to analyzing
the size of the immunological repertoire of the host immunized
with the protein.
Antibodies are often given names that suggest they are spe-
ciﬁc for particular proteins or antigenic sites which always harbor
numerous epitopes. This practice can lead to confusion since an
antibody cannot be speciﬁc for a multiepitopic antigen as a whole
but only for one of its epitopes. There is therefore no clear answer
to the question whether an Mab or a polyclonal antiserum is the
more speciﬁc reagent since it depends on which antigens the inves-
tigator is trying to differentiate (Van Regenmortel, 1998a). An
individual Mab is usually better able to discriminate between two
cross-reactive epitopes than a polyclonal antiserum, although the
antiserum tends to have greater speciﬁcity for a multiepitopic pro-
tein. The reason for this is that themany antibodies in an antiserum
FIGURE 1 |Two overlapping discontinuous epitopes of lysozyme
recognized by Mabs F9-13.7 (A) and HyHEL 10 (B) elucidated by X-ray
crystallography. Thirteen residues of lysozyme (in gray) are recognized by
both antibodies, albeit with different bonding patterns. The rounded
rectangle in gray represents the lysozyme α-helix. The two sets of CDRs
are shown in color and have different orientations on the lysozyme surface.
Three residues (N77, T89, and G102 highlighted with red circles) are not
shared by the two epitopes. Intermolecular contacts are shown by arrows.
Mab HyHEL 10 forms a salt bridge between lysozyme K97 and residue D32
of the H1 antibody loop. Mab F9-13.7 forms salt bridges between lysozyme
residues K97, K96, and H15 and respectively residues E50, D52, and D54 of
the H2 antibody loop (adapted from Lescar et al., 1995, reproduced with
permission).
which recognize the same protein through separate epitopes give
rise to an additive speciﬁcity effect. Since each polyspeciﬁc Ab in
the polyclonal serum cross-reacts with a large number of epitopes
that are different for each Ab, the collective cross-reactive poten-
tial of the antiserum is diluted out which leads to the separate
cross-reactivities of the different antibodies being masked (Tal-
mage, 1959; Richards et al., 1975; Al Moudallal et al., 1982; Parnes,
2004). The ability of the immune system to speciﬁcally recognize
a huge number of multiepitopic antigens is therefore not due to
the existence of myriads of antibodies, each one recognizing a
unique epitope present in only one antigen, but arises from the
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combinatorial effect of several polyspeciﬁc antibodies recognizing
separate epitopes on the same antigen (Wucherpfennig et al., 2007;
Van Regenmortel, 2012).
CAUSATION AND EXPLANATION IN BIOLOGY AND
IMMUNOLOGY
Philosophers usually describe the process of scientiﬁc explana-
tion by the so-called deductive-nomologicalmodel which presents
explanations as being logically deduced from one or other rele-
vant law of nature (Klee, 1997; Psillos, 2002). For instance, the
occurrence of an eclipse will be explained using Newton’s laws
of universal gravitation together with certain initial conditions.
Newton’s laws of motion apply to celestial bodies because they
move in an interstellar vacuum, free from external interference.
On Earth, the laws of Newtonian mechanics explain phenom-
ena only if one adds a ceteris paribus (i.e., other things being
equal) clause to rule out interfering forces such as electromag-
netic forces (Cartwright, 1983). Newton’s laws have sometimes
been blamed for leading scientists to expect that all explanations
in science should be able to provide the precise predictions achiev-
able in astronomy. In physics, there are many well-established laws
that do lead to extremely reliable predictions and have given us a
remarkable understanding of the physical universe. Unfortunately,
this is not possible in biology for the simple reason that there are
no universal laws in biology (Dupré, 1993). Causal explanations
in terms of a single cause acting according to a law of nature are
therefore not possible in the biological sciences.
Causation is a mode of event generation (Bunge, 2003) and
causal relations are relations between successive events and not
between two material objects or between a structure and an
event. A biological event such as the binding reaction between
an antibody and an antigen is thus not caused by the structure
of the reactants. An antibody on its own possesses no causal
efﬁcacy in bringing about a biological activity such as infectiv-
ity neutralization which involves a ternary relationship between
antibody, pathogen, and host and always depends on numerous
immunological and pathophysiological factors.
In biology, only contributory causes can be identiﬁed because
a multiplicity of background conditions or factors are always
involved in bringing about an effect (Van Regenmortel, 2002a).
Because of synergy and various interference phenomena, there is
also no linear relationship between the magnitude of one causal
factor and the magnitude of a biological effect. Since any observed
effect always results from the complex network of interactions and
internal regulations that exist in every biological system, a single
causal factor can never be presented as an explanation since it is
not realistic to assume that the clause “other things being equal” is
relevant when hundreds of background conditions contribute to
an effect. In non-linear dynamic systems, the notion of causality
has very little explanatory value (Berger, 1998; Wagner, 1999).
The immunogenicity of an epitope is a biological property,
partly determined by its intrinsic chemical structure,whichmainly
depends on numerous extrinsic factors such as the host Ig reper-
toire, the presence of appropriate BCRs and T cell help, the
use of adjuvants, the process of antibody afﬁnity maturation,
self-tolerance, and various cellular and regulatory mechanisms
that exist only in the biological context of the immunized host.
Explaining immunogenicity by referring to its multiple “causes”
is therefore not helpful for controlling a process that is always
inﬂuenced by a large number of interdependent and cooperative
biological interactions.
The dictum “structure determines function” has many adepts
among molecular biologists and often leads to the assumption
that there is a linear causal pathway operating in biomolecules
which links gene sequence to protein sequence and then to pro-
tein conformation, binding, and function. Such a pseudo-causal
pathway appears to possess explanatory power because it is pre-
sented in a context-independent manner as if the chemical and
cellular environment did not contribute to the process of protein
folding or that the natural Darwinian selection process that led
to the existence of a functional binding partner could be ignored
(Van Regenmortel, 2002b). Such a hypothesized linear pathway
is often presented as shown in Figure 2, which suggests that the
unidirectional ﬂow of genetic information that occurs from DNA
to protein can be extended to the upper levels of biological com-
plexity present in tissues, organs, and organisms. However, genes
do not cause phenotypic characters and although they contribute
to determining phenotypic traits, they do not act upon them. The
prior state of a thing is also not the cause of its subsequent state,
the caterpillar not being the cause of the butterﬂy (Mahner and
Bunge, 1997, p. 39). Although it has been said that to explain
an event is to provide some information about its causal history
(Psillos, 2002, p. 217), this does not mean that it is possible in
immunology to demonstrate a single chain of successive causes
and effects where each effect is itself the cause of a subsequent
effect. The arrows pointing upwards in Figure 2 should thus not be
interpreted as representing a single causal relation linking events
occurring at different levels and providing an ultimate explana-
tion of an immunological mechanism in terms of the genome.
In the case of antibodies, Ig genes are randomly spliced together
from gene segments and they undergo extensive somatic hyper-
mutation following activation with antigen; antibody speciﬁcity
is therefore determined by genetic mechanisms that are unique to
the immune system.
There is no single upward causality chain linking all the lev-
els of biological organization since the phenotypes observed at
each level result from innumerable interactions between genetic,
epigenetic, biochemical, and environmental factors. Although
the misleading metaphors of codes, instructions, blueprints, and
genetic programs continue to be used to describe the transmis-
sion of information from genes to proteins and phenotypes, the
misconceptions that arose from the use of such terms are now
generally recognized (Kay, 2000; Noble, 2008; Shapiro, 2009).
The correspondence between a particular codon and the amino
acid it codes for is usually described as being arbitrary or sym-
bolic (Maynard-Smith, 2000). However, it is equally plausible that
the code is not arbitrary but originated from the need to have
a pattern of hydropathic complementarity between the peptides
speciﬁed by the sense and antisense strands of DNA molecules
(Blalok, 1990; Tropsha et al., 1992). It is, indeed, remarkable that
there is no exception to the rule that codons and anticodons
always code for amino acids of opposite hydropathicity, i.e., either
hydrophilic or hydrophobic residues. This leads to peptides coded
by the two DNA strands that tend to bind to each other. This
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FIGURE 2 |The reductionist upward causal chain from genes to organisms, and various forms of downward causation that regulates lower
level components in biological systems.This representation does not take into account the inﬂuence of the environment at the various levels (from
Noble, 2012, with permission).
phenomenon explains why peptide analogs that retain the original
hydropathic proﬁle found in a continuous epitope are usually
able to bind the same antibody although they possess little or no
sequence similarity with the original epitope (Hanin et al., 1997;
Van Regenmortel, 1998b).
The earlier confusion between the concepts of gene as a pre-
dictor of phenotypic characters and a developmental factor in
ontogeny has been resolved (Bradie, 2003; Moss, 2003) and it is
now evident that our considerable understanding of the mecha-
nisms that allow genes to be translated into proteins has in fact
given us very little insight on how phenotypic traits are pro-
duced in organisms (Oyama et al., 2001; Oyama, 2009). Although
a gene-centric approach to understanding biological systems is still
sometimes advocated (Brenner, 2010) it is generally accepted that
there is no privileged level of determination in biology at any of
the levels illustrated in Figure 2 and that both bottom up and top
down determination can occur (Mahner and Bunge, 1997; Noble,
2012). Since the hierarchy of levels labeled “up” and “down” are
actually metaphors (Noble, 2012), one can also refer to horizontal
causation for describing the internal causal relations that operate
within the boundaries of each of the different levels.
Any level in the hierarchy of biological complexity can be the
starting point for a causal analysis, provided a certain initial state
of affairs is considered to be in need of an explanation. However,
the explanations must be framed in terms of network causal-
ity and they always have to consider the numerous factors that
simultaneously inﬂuence the system in a given biological con-
text. The upward and downward arrows in Figure 2 therefore
represent only one factor among many others that contribute
to the observed effect. In all cases, a causal link attributed to
one particular factor or mechanism will have to be conﬁrmed
by subsequent experimentation which alters that factor since this
is the only way to establish that the hypothetical cause elicits the
predicted effect in a particular context (Van Regenmortel, 2007).
This means that in immunology, explanations in terms of causal
links must be validated by experimental interventions and manip-
ulations in order to satisfy Woodward’s (2003) requirement of
“making things happen” (see Scientiﬁc Understanding Arises from
the Ability to Successfully Manipulate the Immune System).
REDUCTIONISM AND EMERGENCE IN IMMUNOLOGY
The reductionist mindset is epitomized by the assertion of Crick
(1966): “The ultimate aim of the modern movement in biol-
ogy is to explain all biology in terms of physics and chemistry”.
Most biologists believe that organisms are composed solely of
atoms and molecules without the participation of extraneous or
spiritual forces, and they tend to take the view that biological sys-
tems can therefore be fully described and understood in terms
of the physico-chemical properties of their constituent parts. In
viral immunology, reductionist thinking leads to the expectation
that both cell-mediated immunity (Zajac and Harrington, 2008)
and antibody-mediated immunity to viruses (Neurath, 2008) will
eventually be fully understood in terms of the molecular proper-
ties of T-cell receptors (TCRs), BCRs, antibodies,MHC molecules,
cytokines, and various other cellular constituents.
It is true that methodological reductionism which dissects a
biological system into its constituent parts has been extremely suc-
cessful as a research strategy in molecular biology and immunol-
ogy and this seems to accredit the view that biology is reducible
to physics and chemistry. It is, therefore, somewhat paradoxical
that in recent years biologists have become increasingly dissatisﬁed
with the view that biological systems can be fully explained
in a reductionist manner using physico-chemical principles.
Misgivings about the validity of reductionist explanations in
biology have been expressed at several international meetings
(Bock and Goode, 1998; Van Regenmortel and Hull, 2002;
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Byerly,2003; Kistler,2003;VanRegenmortel,2004a) and the claims
of genetic reductionism which link human traits to genes have
become totally discredited.
Reductionists assume that the behavior of a biological system
can be understood by analyzing the multiple interactions that exist
between its constituents and that the activity of the whole can be
inferred, deduced, calculated, and predicted from the properties of
the parts. Antireductionists disagree and claim that this is not fea-
sible because interconnections and interactions between the parts
as well as certain inputs from the environment give rise to novel,
emergent properties which are absent in the parts taken in isola-
tion and cannot be predicted or deduced from the properties of
the parts (Holland, 1994). Examples of emergent properties are
the viscosity of water (individual water molecules have no vis-
cosity), a melody arising from notes and the immunogenicity of
a protein. Since dissecting the immune system into its compo-
nents severs the connections that link the various parts together in
a functionally integrated manner, essential features that regulate
the system’s behavior are destroyed and it is no longer possible to
account for the workings of the system as a whole (Van Regen-
mortel, 2002a). Negative feedback and feed-forward control lead
to dynamic behavior that cannot be predicted satisfactorily by
linear mathematical models that disregard cooperativity, synergy,
and non-additive effects. Emergent properties have their own dis-
tinctive causal powers exempliﬁed by the downward causation that
occurs when an organism controls biochemical activities that take
place at a lower level.
Proponents of reductionism often claim that explanations of
biological phenomena can be provided without invoking biologi-
cal concepts at all. This leads to “Nothing but-ism” statements of
the type: “Organisms are nothing but physico-chemical systems”
and “the mind is nothing but neural activity” (Van Regenmor-
tel, 2004a). A similar confusion arises when it is claimed that a
biochemical process such as the interaction between actin and
myosin causes the physiological process of muscle contraction. A
frog will jump because it sees a snake and not because a biochem-
ical reaction causes a physiological activity. The biochemical and
physiological processes occur simultaneously and the one cannot
cause the other since both are descriptions at different levels of
the same reaction (Rose, 1998). When the interaction between a
viral epitope and a paratope is described at the molecular level,
it is debatable whether the analysis belongs to the biological ﬁeld
of viral immunology or to the chemical ﬁeld of protein science.
Although such an analysis could be presented as a reduction of
biology to chemistry, it can also be interpreted as an analytical
shift that no longer addresses a biological question, especially if
no attempt is made to study the interaction as a biological recog-
nition phenomenon between pathogen and antibody or as part of
an infectivity neutralization process (Van Regenmortel, 2002b).
Biochemists and structuralists tend to regard the function of a
protein simply as what the molecule does, i.e., its functioning or
activity at the molecular level. However, the function of an enzyme
or an antibody may become meaningful only when the biological
context is taken into account and the study takes place at the cellu-
lar or organismic level. The activity of an enzyme such as trypsin
can be analyzed at the chemical level in terms of which peptide
bonds are cleaved but its biological function may become apparent
only when the enzyme participates in protein degradation and
digestion processes. Similarly, the antigenic and immunogenic
activities of a viral discontinuous epitope may become actualized
only if the epitope is studied when embedded in a native protein at
the surface of a virion or when it interacts with a BCR during the
immunization process. When the activity of an epitope is reduced
to a chemical interaction with an antibody, the functional impli-
cations of such a recognition event cannot be predicted especially
if the binding occurs simultaneously with numerous reactions of
other antibodies present in a polyclonal antiserum. Extrapolating
from the neutralizing activity observedwith oneMab to the collec-
tive neutralization potential of an antiserum is always hazardous
(Mascola et al., 1997) since the initial binding of an antibody often
leads to conformational changes in the antigen that modify its
ability to interact with other antibodies.
The structural parameters of an epitope bound to anMab relate
only to its binding activity as an antigen since the epitope struc-
ture is unlikely to be identical with the immunogenic structure
that initiated the immunization process and gave rise to the Mab
(Wilson and Stanﬁeld, 1994; Bosshard, 2001; Kim et al., 2011).
Recent studies involving deep sequencing of antibodies in human
serum have shown that the initial immunogen which triggers the
afﬁnity maturation process leading to a particular nMab usually
recognizes a germline-like version of the BCR that differs consid-
erably from the one corresponding to the mature Mab, implying
that different epitopes are involved (Xiao et al., 2009).
Questions regarding the origin of the binding activity of anti-
bodies cannot be answered in a mechanistic manner by analyzing
their internal structure. The answer as to why antibodies are orga-
nized the way they are does not lie inside but outside of the
antibody molecule. The answer, therefore, cannot be obtained
in a reductionist manner by analyzing the antibody’s chemical
composition and structure (Cohen and Stewart, 1994, p. 243).
Instead of looking for structural explanations of an observed
functional activity, biologists emphasize functional explanations
for a currently observed biological structure in terms of natu-
ral selection and superior ﬁtness in the past (Rosenberg, 1994,
p. 193; Van Regenmortel, 2002a). Using the terminology of Mayr
(1961) biologists rely on so-called ultimate, historical causes rather
than on proximate causes for explaining the functional activity of
biomolecules (Laland et al., 2011).
Predicting the binding and functional activity of a protein de
novo solely on the basis of its structure remains an impossible
task. What is possible is to predict the probable activity of a pro-
tein by comparison with a structurally similar protein of known
activity. In the case of antibodies, their multiple binding activities
dependon the existenceof a relational nexuswith several unknown
and unpredictable partners. Attempts to predict the neutralizing
capacity of an antibody from its structure is even more unre-
alistic since it involves a ternary interaction between antibody,
antigen, and host which is entirely context-dependent. Further-
more, it is impossible to instruct the immune system to produce
polyclonal antibodies endowed with a synergistic neutralizing
capacity, regardless of whether the structural correlates of that
activity are known or unknown.
Vaccination as an immunological intervention is meaningful
only at the level of an entire organism, since organs, tissues, or
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molecules cannot be vaccinated. The protection against disease
which is the goal of all vaccination procedures therefore remains
ﬁrmly anchored in the complexities of biological systems and can-
not be reduced to the chemical level of a molecular interaction
(Van Regenmortel, 2004b).
HUMAN INTENTIONALITY AND RATIONAL
DESIGN STRATEGIES
The term “design” can be deﬁned as the deliberate conceiving
of an artiﬁcial, novel object or process by an intelligent being.
The designer’s task is to pose and solve an inverse problem
namely to imagine, using available knowledge, what would bring
about a desired outcome (Bunge, 2003). In most cases, possi-
ble solutions must be tested by trial-and-error experiments until
the preset goal is attained. This means that opposing rational
design and empirical approaches in vaccine research (Karlsson-
Hedestam et al., 2008) is fallacious since all scientiﬁc knowledge
in the experimental sciences is derived from empirical testing that
is necessarily planned and analyzed in a rational manner. One
empirical research area that may justify additional investigations
is the use of chemically inactivated HIV-1 immunogens. Several
new methods are currently available to chemically inactivate the
virus while retaining the functional integrity of the Env protein
(Van Regenmortel, 2011a and references therein). It may thus be
worthwhile to re-examine thepotential value of a killed, genetically
modiﬁed HIV-1 vaccine, provided the safety of such material has
been established.
Doing something by design is synonymous to doing it inten-
tionally, and human intentions tend to be perceived as the cause
of all human behavior and actions. This often leads to the anthro-
pomorphic fallacy that the behavior and activities of all living
organisms can be understood in terms of intentions and pur-
poses. Since all the individual components of a biological system
contribute in an integrated manner to its functioning and survival,
living organisms may give the impression of having been designed.
However, biologists no longer use psychological notions of inten-
tions, design, and purposes to explain biological functions since it
is universally accepted that organisms were fashioned and shaped
by the ﬁlter and pressure of Darwinian natural selection (Ruse,
2002; Hanke, 2004; Van Regenmortel, 2007).
It is nowadays commonly believed that rational designoffers the
best prospects for developing new drugs and vaccines (Bramwell
and Perrie, 2005; D’Argenio and Wilson, 2010) and that this
approach is vastly superior to the empirical screening and trial-
and-error strategies used in the past. It has been claimed, for
instance, that: “One of the goals of research in biotechnology is
to transform the process of developing a drug from a trial-and-
error empirical operation into a rational, structure-based process”
(Amzel, 1998). This denigration of empiricism contradicts the
fact that even if a molecule or a vaccine has been designed fol-
lowing structure-based predictions, it is still necessary to screen
and verify its activity in the biological context in which it is to
be used. The label “rational” applied to modern vaccine design is
similar to the concept of “rational drug design”which describes the
structure-based strategy used in drug development (Kuntz, 1992).
This strategy relies on knowledge of the 3D structure of a biolog-
ical target for predicting and designing candidate molecules that
will bind with high afﬁnity and selectivity to the target and inhibit
its biological activity. This computer-assisted strategy based on
structural bioinformatics and molecular docking has been highly
successful, for instance, for developing the antiretroviral drugs
that are used to inhibit various HIV enzymes (Wlodawer, 2002;
De Clercq, 2009; LaFemina, 2009).
In the biochemical and biomedical literature, the term rational
is used to refer to any procedure that is based on the common
sense decision to focus on elements of the system under study for
which molecular information is available (Obeid et al., 1995; Van
Regenmortel, 1999). “Rational” is then synonymous with “reason-
able” or “intelligent” and does not correspond to the notion of
rationality found in the philosophy of science and which is used
in statements such as “scientiﬁc judgment is guided by rational-
ity” (Newton-Smith, 1981; Giere, 1988). It has been suggested that
rationality should no longer be used as the ultimate justiﬁcation
for scientiﬁc procedures and decision making and that it may be
preferable to replace it by the concept of “bounded rationality”
(Gigerenzer and Selten, 2001; Lucas and Roosen, 2010). Bounded
rationality recognizes that when scientists have to reach decisions
on how to proceed, they operate under three unavoidable con-
straints linked to (1) the limited information they have, (2) the
limited capacity of their minds to process huge amounts of data,
and (3) the limited amount of time they have to make a decision.
One consequenceof these limitations is that it is thenno longer fea-
sible for them to achieve the optimization process that in principle
is required from a genuinely “rational” design procedure.
There is one additional reason for being skeptical of the claim
that the rational design of vaccines is a realistic endeavor. Although
it is possible to rationally design an epitope or antigen so that it
will have an improved structural complementarity to one partic-
ular nMab, this only represents antigen design in the context of a
single epitope–paratope pair and it should not be called immuno-
gen design. When authors discuss the rational design of an HIV-1
vaccine (Douek et al., 2006; Walker and Burton, 2010; Nabel et al.,
2011), they only refer to studies that improve the degree of com-
plementarity in one epitope–Mab pair and they do not clarify
how an improved antigen could actually be “designed” to become
an immunogen capable of generating protective antibodies. Pre-
sumably this would require an investigation of the numerous
factors, extrinsic to epitope–paratope recognition, that originate
in the immunized host and control the type of protective immune
response that a vaccine immunogen is expected to elicit. Optimiz-
ing the binding activity of an antigen by structure-based design
is clearly not equivalent to controlling or improving by trial-and-
error the numerous biochemical and cellular interactions involved
in the generation of a neutralizing immune response. Antigen
design is actually masquerading as immunogen design because of
the unacknowleged, implicit assumption that antigenic reactivity
necessarily entails an immunogenic capacity to produce antibod-
ies similar to the one used as template for designing the antigen.
Although some authors acknowledge the difference between anti-
genicity and immunogenicity, they still tend to adhere to the view
that an antigen designed to ﬁt an nMab will also be an efﬁcient
vaccine immunogen able to elicit neutralizing and protective anti-
bodies. All the experimental immunization results obtained so far
(Van Regenmortel, 2011a) as well as the nature of the biological
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processes and mechanisms underlying antibody synthesis and
maturation speak against such an assumption (Verkoczy et al.,
2011; Chen et al., 2012). It is therefore not astonishing that all
the studies reporting the successful rational design of a viral anti-
gen have failed to demonstrate that the engineered antigen is also
an effective vaccine immunogen (Van Regenmortel, 2012).
REVERSE VACCINOLOGY AND THE RATIONAL DESIGN
OF HIV-1 ANTIGENS
The concept of reverse vaccinology (RV) was introduced in the
ﬁeld of bacterial vaccines by Rappuoli (2001) about 10 years
ago. RV does not attempt to develop vaccine candidates by the
usual approach of fractionating bacterial extracts and determining
which antigens are able to induce a protective immune response
but by predicting potential vaccine immunogens using bioinfor-
matics analyses of entire bacterial genomes. In silico analysis of
the genome provides a list of all the surface-exposed proteins
that the pathogen is able to express and these proteins are then
produced by high-throughput technologies and tested for their
immunoreactivity with patient sera as well as for their ability to
induce protective antibodies (Rappuoli and Bagnoli, 2011). This
strategy was called “reverse” vaccinology because the investiga-
tors operate in a so-called reverse manner, i.e., starting from
the genome rather than from the organism, to discover which
proteins are potential vaccine immunogens. This genome-based
strategy has the advantage that hundreds of bacterial proteins are
identiﬁed as candidate immunogens even if the bacteria cannot
be cultivated.
In virology, RV has a different meaning altogether and refers
to the strategy of generating a vaccine from the known crystal-
lographic structure of nMabs bound to viral epitopes. The term
“reverse” is used metaphorically in the sense that the investigator
is trying to generate a vaccine starting from neutralizing antibod-
ies instead of trying to generate such antibodies by immunization
(Burton, 2002; Walker and Burton, 2010). It is not clear, however,
which vaccine discovery process is being reversed since the bnMab
is simply used as a template to reconstruct its epitope outside
the context of the natural antigen, using structure-based design
technology. The assumption is then made that the reconstructed
antigen designed to ﬁt the bnMab will possess the immunogenic
capacity of inducing a polyclonal antibody response with the same
neutralizing capacity as the Mab.
Since the RV approaches used for developing bacterial and
viral vaccines are completely different it would be preferable
to call them genome-based and structure-based RV, respectively
(Van Regenmortel, 2011b). Both strategies require trial-and-error
experimentation to ascertain which candidate bacterial or viral
proteins are able to act as effective vaccine immunogens, and
it is therefore misleading to present RV as a rational design
procedure that overcomes the empirical nature of all vaccine sci-
ence (Mascola, 1999; Karlsson-Hedestam et al., 2008). In section
“Human Intentionality and Rational Design Strategies”, it was
argued that the development and discovery of vaccine immuno-
gens by rational design is actually a misnomer. The ensuing
discussion will therefore only consider attempts to rationally
design antigens able to bind Abs without making the assump-
tion that what is being designed is also a vaccine immunogen
(Sattentau and McMichael, 2010).
In a recent comprehensive review paper entitled: “Structure-
based vaccine design in HIV: blind men and the elephant,” Pejchal
and Wilson (2010) referred to the Indian tale of three men trying
to describe an elephant and reaching different conclusions because
they touchdifferent parts of the animal. They compared this unsat-
isfactory procedure to theway investigators try to identify potential
HIV vaccine targets by determiningwhich Env regions are targeted
by individual nMabs. An amusing illustration of this approach is
shown in Figure 3 where one vulnerable “epitopic” region in the
animal has been hit by a single Mab arrow.
The question of whether an effective vaccine can be developed
by focusing the immune response on a single vulnerable site or
epitope is a controversial issue (Scheid et al., 2009; Walker et al.,
2009, 2010; Lynch et al., 2011; Moore et al., 2011). An alterna-
tive approach is depicted in the painting of Mantegna (Figure 4)
which illustrates symbolically that an effective vaccine may require
multiple vulnerable regions to be targeted by a polyclonal Ab
response (Doria-Rose et al., 2012).
FIGURE 3 |This cartoon illustrates how one vulnerable epitope region in an elephant is successfully hit by a single nMab arrow.
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FIGURE 4 |The painting of St Sebastian by Mantegna in the Ca d’Oro
museum inVenice.The arrows symbolize a polyclonal antibody response
which is not directed to a single vaccine target.
Although the advent of Mabs has revolutionized our under-
standing of immunochemistry by making it possible for investi-
gators to successfully dissect polyclonal Ab responses in terms of
single epitope–paratope interactions, the use of Mabs also had
the unfortunate consequence that vaccine hunters have tended to
focus on individual epitopes as elicitors of neutralizing Abs. This
led them to neglect the synergistic effects that result from the col-
lective neutralizing activities of antibodies directed to different
epitopes (Laal et al., 1994; Mascola et al., 1997; Zwick et al., 2001;
Van Regenmortel, 2012).
Attempts to design improved HIV-1 antigens have used as tem-
plates a small number of nMabs that recognize different antigenic
sites of the Env protein such as the conserved CD4-binding site
(CD4bs; Burton et al., 1994; Kwong et al., 1998; Zwick et al.,
2003; Li et al., 2007), the CD4-induced (CD4i) antigenic site that
becomes accessible after gp120 interacts with CD4 (Labrijn et al.,
2003), the semiconserved V3 loop (Javaherian et al., 1989; Zolla-
Pazner, 2004; Zolla-Pazner and Cardozo, 2010), the membrane-
proximal external region (MPER) antigenic site (Zwick, 2005), and
the glycan antigenic site (Scanlan et al., 2002; Pantophlet, 2010). It
must be emphasized that each antigenic site harbors a large num-
ber of different epitopes. This means that if an immune response
directed to one HIV-1 antigenic site is considered to represent a
single speciﬁcity, this does not exclude that a large number of
different Abs will recognize overlapping targets within the same
antigenic region (Walker et al., 2010).
Various strategies have been used to improve the antigenic reac-
tivity of the epitopes recognized by Mabs by reconstructing the
epitopes outside the viral protein context in which they occur.
Such strategies include (1) hyperglycosylation (Pantophlet et al.,
2003a), (2) amino acid substitutions (Pantophlet et al., 2003b),
(3) stabilization of the CD4-bound state by introducing cross-
links or deleting variable loops (Dey et al., 2007; Zhou et al., 2007;
Wu et al., 2010), and (4) immunofocusing, i.e., decreasing the
ability of the CD4bs to bind to non-neutralizing antibodies while
retaining the capacity to bind to bnMabs (Pantophlet and Burton,
2003). Although some of the engineered antigenic sites that were
obtained reacted better with bnMabs, none of them were found
to be effective immunogens able to induce broadly neutralizing
antibodies (Pejchal and Wilson, 2010; Kong and Sattentau, 2012;
Van Regenmortel, 2012).
Attempts were also made to improve the antigenic reactivity
of the MPER continuous epitopes recognized by Mabs 2F5, 4E10
(Muster et al., 1993; Julien et al., 2008) and Z13 (Nelson et al.,
2007). This was done by adding ﬂanking residues to the core
epitopes (Tian et al., 2002), constraining the epitopes in various
conformations (Joyce et al., 2002; Ho et al., 2005), mimicking the
conformation of the epitopes when they are bound to bnMabs
(Ofek et al., 2004), and grafting the epitopes into various protein
scaffolds (Arnold et al., 2009; Burton, 2010; Correia et al., 2010;
Ofek et al., 2010a; Guenaga et al., 2011). Some of these modiﬁca-
tions increased the binding capacity of the peptides but they did
not endow them with the capacity to elicit bnAbs (Law et al., 2007;
Guenaga et al., 2011). This may be due to the fact that the short
core peptide regions recognized by 2F5, 4E10, and Z13 do not
constitute the full epitopes since there is evidence that the epitopes
are chemically heterogeneous and include lipid moieties that par-
ticipate in the binding reaction through hydrophobic interactions
(Scherer et al., 2010; Ofek et al., 2010b). Other composite HIV
epitopes have been shown to include glycan moieties (McLellan
et al., 2011). It has been shown that hydrophobic residues of the
long CDR H3 loop of Mab 2F5 are able to insert into the viral
membrane, producing major conformational rearrangements in
both epitope and paratope and illustrating the role of induced ﬁt
dynamics in antigen–antibody interactions (Alam et al., 2009; Kim
et al., 2011).
Epitopes in certain HIV-1 strains may become inaccessible
to antibodies following hyperglycosylation, mutations or con-
formational changes, a phenomenon called antigenic masking
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(Krachmarov et al., 2005). Thismakes it impossible for suchHIV-1
strains to be neutralized by certain nAbs since epitope exposure is
usually a prerequisite for neutralization by antibody molecules
(for a review, see Pantophlet, 2010). Epitopes in the V3 loop
that remain unmasked in many HIV-1 strains and are recog-
nized by bnMabs have been identiﬁed using signature motifs of
2–4 residues and it has been suggested that cocktails of such
epitopes may be good vaccine candidates (Agarwal et al., 2011).
Recently, it was shown that cross-clade nAbs could be induced by
using V3-scaffold immunogens in a DNA prime/boost regimen
(Zolla-Pazner et al., 2011).
Many attempts have been made to develop vaccine immuno-
gens by expressing surface loops containing continuous epitopes
of different viruses as recombinant proteins (Hofnung and Char-
bit, 1993) but even this fairly straight-forward approach did not
produce any effective viral vaccine (Van Regenmortel and Muller,
1999). Compared to simple loop structures, reconstructing HIV-
1 discontinuous epitopes (Moore and Ho, 1993; VanCott et al.,
1995) and presenting them in the required conformation at the
surface of a carrier or scaffold protein is a much more difﬁcult
task and all attempts to produce effective HIV-1 vaccine immuno-
gens in this way have so far been unsuccessful (Burton, 2010;
Azoitei et al., 2011).
An even more difﬁcult task is to reconstruct epitopes that arise
from the quaternary structure of viral proteins. It has been known
formore than40 years that such epitopeswhichwere initially called
neotopes (seeVan Regenmortel, 2009b, 2012) are present in capsid
and membrane proteins and are easily detectable by appropriate
immunoassays (Neurath and Rubin, 1971; Van Regenmortel and
Neurath, 1985). These epitopes are nowadays commonly referred
to as quaternary epitopes which is a somewhat odd terminology
since it would correspond to calling continuous and discon-
tinuous epitopes, primary and tertiary epitopes, respectively.
Neotopes arise from the juxtaposition of residues in neighbor-
ing protein subunits or from conformational changes induced by
intersubunit interactions (Van Regenmortel, 2009b). They were
shown to be present in HIV-1 gp120 trimers only fairly recently
although they appear to be very common (Broder et al., 1994;
Cho et al., 2000; Walker et al., 2009; Pantophlet, 2010; Robinson
et al., 2010; Zolla-Pazner and Cardozo, 2010; Pancera et al., 2010;
Wu et al., 2011a).
Mab 2902 is the ﬁrst antibody directed to a neotope of the
Env protein which had its structure elucidated (Gorny et al., 2005;
Kimura et al., 2009). This antibody which is highly strain-speciﬁc
has a 21-residue long CDR H3 loop which protrudes from the
paratope surface and recognizes a neotope comprising portions of
the V2 and V3 loops (Honnen et al., 2007; Changela et al., 2011).
The two somatically related Mabs, PG9 and PG16 which neutral-
ize about 80% of primary HIV-1 isolates also recognize a V2V3
neotope (Walker et al., 2009; Pejchal et al., 2010; Pancera et al.,
2010). The PG9 neotope contains a single β strand and two glycans
that form a canyon structure into which the long CDR H3 loop of
Mab PG9 inserts itself (McLellan et al., 2011). Many anti-HIV-1
antibodies have been found to possess longCDRH3 regions (Stan-
ﬁeld et al., 2004; Huang et al., 2005; Burke et al., 2009; Changela
et al., 2011) although they do not use their protruding loops to
reach recessed epitopes in the same way as Mabs PG9 and 2909.
Unfortunately, it is not known how antibodies with long CDR H3
loops can be induced by immunization.
Reconstructing HIV-1 neotopes by structure-based design may
turn out to be an impossible task, partly because of the unsta-
ble and transient conformation of Env trimers (Du et al., 2009)
which can alternate between open and closed quaternary con-
formations (Harris et al., 2011). It remains unclear whether such
transient neotopes are advantageous for inducing neutralizing
antibodies because their conformational variability is able to facil-
itate induced ﬁt adjustments and BCR recognition. In studies with
other HIV-1 epitopes, there are conﬂicting reports on whether
immunogenicity is enhanced by increasing or decreasing epitope
ﬂexibility (Dey et al., 2009; Moseri et al., 2010; Ofek et al., 2010a;
Guenaga et al., 2011).
In recent years, large numbers of additional bnMabs have
been isolated from HIV-1 infected individuals (Scheid et al., 2009;
Simek et al., 2009; Stamatatos et al., 2009; Corti et al., 2010)
which demonstrates that the human immune system is able to
induce such neutralizing antibodies more frequently than previ-
ously thought (Wu et al., 2010; Scheid et al., 2011; Tomaras et al.,
2011; Overbaugh and Morris, 2012). This has led to the expecta-
tion that additional HIV-1 epitopes and potential vaccine targets
will continue to be discovered and that this should facilitate and
guide the design of effective vaccine immunogens (Sattentau and
McMichael, 2010). Such optimism assumes that the identiﬁca-
tion of additional HIV-1 epitopes somehow entails that there is
then an increased probability that the rational design of HIV-
1 vaccine immunogens will become more feasible. It would be
equally unwarranted to claim that discovering additional bnMabs
useful for passive immunotherapy is likely to improve our ability
to determine which immunogens are able to elicit such protec-
tive antibodies by active immunization. Although the passive
administration of rare human anti-Env bnMabs to non-human
primates (NHPs) can protect the animals from virus infection,
this type of successful immunotherapy does not in any way tell
us how such protective antibodies can be elicited by vaccination.
It is of course possible to improve the paratope binding efﬁ-
cacy of a particular Mab intended for passive immunotherapy,
using structure-based design. However, as discussed in section
“Human Intentionality and Rational Design Strategies”, what is
not feasible is to rationally design an immunogen that will elicit a
protective polyclonal antibody response of predetermined efﬁcacy
(Van Regenmortel, 2012).
THE BOTTLENECK OF ANTIBODY AFFINITY MATURATION
Considerable knowledge is available regarding the genetic basis of
antibody diversity. It has been known for many years that initial
exposure to any antigen elicits a primary immune response char-
acterized by low-afﬁnity germline-encoded antibodies (Marks,
1994). In naïve human individuals who have not yet encountered
a viral antigen, a primary response is initiated when the antigen
binds to germline BCRs derived by random genetic recombina-
tion from a small pool of variable (V), diversity (D), and joining
(J) gene segments present in the human genome (Arnaout et al.,
2011). These BCRs which arise from rearranged heterodimers of
light andheavy chains are highly polyspeciﬁc and reactweaklywith
a large number of different antigens, allowing the immune system
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to initiate a response against virtually any antigen. Structural
analyses have shown that the polyreactivity of germline Abs is
enhanced by the ﬂexibility and conformational versatility of the
CDRs (Manivel et al., 2000, 2002; James et al., 2003; Yin et al., 2003;
Khan and Salunke, 2012). The polyreactivity of germline Abs and
of the initial response to HIV-1 Env antigens is a general property
of the human immune system and is not a special feature of HIV
immune responses. HIV-1 antibodies have been shown to cross-
react with cardiolipin (Haynes et al., 2005a), host cell and gut ﬂora
antigens (Liao et al., 2011), as well as with histones, ribonucle-
oprotein, centromere B, and Ro/Sjogren syndrome autoantigen
(Morris et al., 2011). It has been postulated that B cells that pro-
duce autoreactive Abs may trigger tolerance mechanisms which
could eliminate bnAb precursors (Haynes et al., 2005b).
After initial binding of the antigen to germline BCRs, a stochas-
tic process of somatic hypermutation occurs in the variable regions
of Ig genes at rates several logs higher than in other genes. This
leads to the selective expansion of B cell clones that possess high
afﬁnity BCRs for the immunizing antigen and to the proliferation
of plasma cells that secrete antibodies with increased afﬁnity for
the antigen.
Advances in large scale pyrosequencing of the antibodyome,
i.e., of the complete set of antibody sequences present in an organ-
ism at a given time, has allowed deep sequencing of V (D) J gene
segments and Ig genes (Fischer, 2011). This made it possible to
identify which germline Ig genes are used in a given B cell matu-
ration process and to follow the mutational pathway from naïve,
low afﬁnity B cells to high afﬁnity mature BCRs and antibodies
(Dimitrov, 2010).
Early studies of antigen-driven maturation in HIV-1 antibodies
showed that extensive somatic hypermutation occurred in their
variable regions amounting to an average mutation frequency
of 10–20% (Andris et al., 1991; Moran et al., 1993; Huang et al.,
2004). When the germline predecessors of the afﬁnity-matured
HIV-1 Mabs b12, 2G12, and 2F5 were examined, it was found
that the antibodies derived from naïve B cells did not bind to
the epitopes that were recognized by mature Mabs (Xiao et al.,
2009). Subsequent studies revealed that most anti-HIV-1 bnMabs
were highly mutated antibodies which had undergone a prolonged
afﬁnity maturation process, thereby acquiring a high neutral-
ization potency (Mouquet et al., 2011). The afﬁnity maturation
observed in HIV-1 antibodies was much more extensive than
the 5–10% mutation frequency usually observed with antibod-
ies directed to other viruses (Zhu et al., 2008; Chen et al., 2012). In
Mab VRCO1 which neutralizes about 90% of the HIV-1 strains
tested, more than 60 amino acids in the variable region were
found to differ from the germline sequence, which amounts to
a 30% mutation frequency (Zhou et al., 2010; Scheid et al., 2011;
Wu et al., 2011b). In the bnMabs PG9 and PG16, about 20% afﬁn-
ity maturation was present (Pancera et al., 2010) whereas in the
less broadly neutralizing Mab2909 the degree of afﬁnity matura-
tion was considerably less. There is now abundant evidence that
the degree of afﬁnity maturation in bnMabs correlates with their
neutralizing potency.
The germline-like versions of all these Mabs showed little or no
measurable binding to HIV-1 Env, indicating that the immuno-
gens which initiated the afﬁnity maturation process are unlikely
to have been the epitopes recognized by the mature bnAbs used as
templates in the RV experiments. These ﬁndings therefore inval-
idate one of the assumptions underlying attempts to develop an
HIV-1 vaccine by rational design (Pantophlet, 2010), namely that
the epitopes recognized by matured bnMabs can be used to trig-
ger the afﬁnity maturation process required to obtain protective
antibodies.
Some investigators have been unwilling to admit that these
ﬁndings have led to an impasse in structure-based RV. If somatic
hypermutation is indeed a prerequisite for obtaining anti-HIV-1
bnAbs, then it may be mandatory to use vaccine immunogens
able to bind germline BCRs rather than immunogens designed to
mimic the epitopes recognized by mature bnMabs. It may also be
necessary to administer vaccine immunogens over several months
or years if large numbers of amino acid changes must accumulate
in germline precursor genes to obtain antibodies of sufﬁciently
high afﬁnity and neutralization breadth (Gray et al., 2011; Euler
et al., 2012). On the other hand, it is not known if all the muta-
tions observed in matured antibodies are required for achieving an
adequate binding and neutralization potency (Burton et al., 2005),
nor if the B cells expressing BCRs that bind with low afﬁnity to
certain viral antigens will be able to outcompete B cells expressing
BCRs that bind to other epitopes with higher afﬁnity.
It has been argued by some that a low afﬁnity interaction
between a naïve B cell and an HIV-1 epitope may be sufﬁcient
for initiating the afﬁnity maturation process required for develop-
ing a protective immune response (for a review, see Van Bubnoff,
2010). However, an even greater hurdle may have to be overcome
if it turns out that a stochastic somatic hypermutation process
which could follow millions of different pathways (Zhu et al.,
2011) and may have to be guided and controlled in every vac-
cinated individual, is a requirement for developing a protective
immune response. This new appreciation of the importance of
somatic hypermutation in BCRs has led to the realization that the
strategy of using as vaccine immunogens epitopes designed to ﬁt
mature bnMabs had little chance of succeeding since the required
afﬁnity-maturedBCRsdonot exist innaïve, vaccinated individuals
(Chen et al., 2012).
Attempts are currently being made to try to modify Env
molecules so that they become able to bind germline BCRs or
maturation intermediates (Wu et al., 2011b). Glycan-depleted Env
molecules have been obtained that bind to unmutated precursors
of Mab 2F5 and 4E10 but these were unable to elicit neutralizing
antibodies (Ma et al., 2011).
SYSTEMS BIOLOGY AND THE IDENTIFICATION OF IMMUNE
CORRELATES OF PROTECTION
Systems biology is sometimes presented as a research strategy
that grew out of the realization that studying separately the
individual components of a complex biological system would
not lead to an understanding of how the whole system works
(Cornish-Bowden, 2011). Since biological systems possess emer-
gent, functional properties that are absent in their constituents
parts and are characterized by dynamic networks, regulatory
mechanisms, robustness, and modularity, it seemed impossi-
ble to explain their integrated behavior by considering only
events occurring at the level of individual macromolecules and
www.frontiersin.org July 2012 | Volume 3 | Article 194 | 11
“ﬁmmu-03-00194” — 2012/10/25 — 11:11 — page 12 — #12
Van Regenmortel Reductionist thinking in HIV vaccinology
cells (Van Regenmortel, 2004b; O’Malley and Dupré, 2005;
Mazzocchi, 2008).
Systems biology is an attempt to describe the multiple interac-
tions between all the parts of a biological systemby focusing on the
dynamics of the entire system (Ideker et al., 2001; Kitano, 2002).
Since the immune system utilizes the dynamic interaction of a
wide array of biomolecules, cells, and tissues, the resulting com-
plexity makes the study of immune responses particularly apt to a
systems biology approach (Aderem and Smith, 2004). Genomics,
proteomics, and other “omics” technologies based on multiplex
microarrays, high-throughput sequencing, and bioinformatics are
the methods used for this purpose which have made it possible, for
instance, to identify candidate antigens for diagnostic, therapeu-
tic, and vaccine applications (Van Regenmortel, 2007). Systems
biology is sometimes criticized for being a data-driven approach
that cannot lead to the scientiﬁc discoveries that follow from
hypothesis-driven research (Allen, 2001; Wilkins, 2001) although
some authors argue that both approaches are complementary (Kell
and Oliver, 2004). It has been suggested that because living organ-
isms have evolved, in response to changing environments, through
the accumulation of random, error-prone changes, they devel-
oped a type of complexity different from the complex law-like
behavior of their underlying physico-chemical constituents (Kel-
ley and Scott, 2008). Biological science therefore does not exhibit
the regularities found in the physical sciences and biologists are
only able to explain phenomena by positing mechanisms and
making predictions without actually offering explanations of how
the mechanisms under investigation function. This has led many
biologists to adhere to a viewpoint called “epistemological antire-
ductionism” (Nagel, 1998) and to opt for some form of holism,
emergentism (Gatherer, 2010), or relational biology (Rosen, 1991;
Cornish-Bowden, 2006), while at the same time accepting that
many biological phenomena are too complex to be comprehended
by human intelligence (Gannon, 2007).
In vaccinology, systems biology approaches have been used
mainly for predicting vaccine-induced immunity (Pulendran et al.,
2010; Oberg et al., 2011). A proof-of-concept study was done by
identifying patterns of upregulated gene expression, called molec-
ular signatures, that were induced in humans vaccinated with the
yellow fever vaccine YF-17D (Querec et al., 2009). This vaccine is
one of the most successful vaccines ever developed and it was pos-
sible to correlate parameters such as magnitude of antigen-speciﬁc
CD8+ T cell responses and several molecular signatures with the
development of protective immunity against yellow fever. A major
shortcoming of such studies is that it is very difﬁcult to establish if
any correlations revealed by genomics or proteomics analyses are
causally linked to protection. Genomics analyses may reveal, for
instance, that following an immunization protocol, hundreds of
genes are up- or downregulated. However, since several gene prod-
ucts always act in combination to generate biological functions, the
resulting functional diversity is truly staggering, leading to num-
bers of potential combinations of causal factors that are larger than
the total number of atoms (1080) in the Universe (Feytmans et al.,
2005; Noble, 2006).
It should also be evident that the presence of immune correlates
of protection in vaccines can only be identiﬁed retrospectively after
an effective vaccine has been developed empirically. In individuals
who have survived a natural infection and are protected against
reinfection, it could also be feasible to look for immune correlates
of protection. However, this is not possible in the case of HIV
infection since there are no individuals who have cleared infec-
tion and are subsequently immune to reinfection. Studies with
long-termnon-progressors and elite controllers of HIV-1 infection
(Okulicz, 2012) are also of little value since it is not possible with
such individuals to exclude an innate or genetic predisposition to
non-infection nor to predict which effector functions would be
mediated by an adaptive vaccine-induced immunity (Koup et al.,
2011). Since it is also impossible to determine immune correlates
of protection from failed HIV-1 vaccine trials, it is not astonishing
that past attempts to identify such correlates have been unsuc-
cessful. The recent RV144 vaccine trial which showed a modest
level of efﬁcacy (Rerks-Ngarm et al., 2009) is the ﬁrst instance
when it became possible to test if immunological assays could
serve as surrogate endpoints for HIV-1 infection (Nakaya and
Pulendran, 2012; Rolland and Gilbert, 2012). However, the RV144
trial was not designed to identify immune correlates of protec-
tion and a retrospective analysis of the small number of samples
available from this low efﬁcacy trial was unlikely to reveal which
aspects of the antibody response correlated with immune pro-
tection (Koup et al., 2011). Only the presence of IgG antibodies
to the V1/V2 loops was found to show some correlation with
a limited protection against HIV infection in the ﬁrst year of
the trial.
The use of NHP models of HIV infection such as simian
immunodeﬁciency virus (SIV) and simian-HIV virus (SHIV) for
evaluating immune correlates is also unsatisfactory because of the
differences in disease pathogenesis and immune responses in HIV,
SIV, and SHIV infections (Koup et al., 2011). It is also no longer
generally accepted that showing protection in NHPs should be a
gatekeeper for advancing a particular vaccine product into human
efﬁcacy trials (Shedlock et al., 2009; Thomas, 2009; Greek, 2012).
A particular product that works in macaques may not work in
humans and a strategy that shows no efﬁcacy in NHPs could
nevertheless work in humans. Animal models are poor predic-
tors for human responses partly because results depend on the
viral strains and doses used for challenge experiments and on the
routes of infection (Thomas, 2009). Although it may theoreti-
cally be justiﬁed to pursue exploratory small-scale human trials
when no evidence is available to show that the approach being
tested works in NHPs, it is recommended that NHP studies should
always be used in the preclinical evaluation of HIV-1 vaccines
(Morgan et al., 2008).
SCIENTIFIC UNDERSTANDING ARISES FROM THE ABILITY TO
SUCCESSFULLY MANIPULATE THE IMMUNE SYSTEM
In recent years, many authors have stressed the need to embark
on large scale basic research programmes in order to increase our
understanding of the human immune system and of HIV-1 anti-
genic structure and pathogenicity (Thomas, 2009; McElrath and
Haynes, 2010; Virgin and Walker, 2010). Such recommendations
arise from the realization that our current scientiﬁc knowledge is
too limited to enable us to instruct the human immune system
to generate a protective response against HIV-1 infection. It is
not clear, however, whether an increase in our basic knowledge
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of immunology and of the way bnAbs develop in certain HIV-1
infected individuals will enable us to elicit such antibodies by
vaccination.
Instead of emphasizing the importance of theories and basic
knowledge for achieving scientiﬁc understanding and solving
problems in applied science, Hacking (1983) in his inﬂuential
book Representing and Intervening, suggested that it is the abil-
ity of experimentalists to successfully manipulate a given system
that gives them the conﬁdence that their scientiﬁc constructs and
entities are real and that a particular scientiﬁc explanation is ade-
quate. Whereas observation alone may not justify a belief in the
reality of an invisible fuzzy entity such as an epitope, it is our abil-
ity to successfully manipulate it in an experiment that convinces
us that the entity exists. In other words, we need to interfere with
the material world in order to obtain knowledge about it and our
scientiﬁc understanding increases because we are able to intervene
in a system and successfully manipulate the phenomenon under
investigation (Kelley and Scott, 2008). This means that we “under-
stand” the immune system when we can manipulate and control it
and are able, for instance, to achieve protective immunity by vac-
cination (Kumar et al., 2012). An understanding of the immune
system is thus achieved because of a prior successful interven-
tion. This is different from the usual assumption that we need to
increase our understanding of basic immunology in order to be
able to manipulate and control the immune system.
In his book Making Things Happen, Woodward (2003, p. 9)
emphasized that causal relations and explanations are important
tohumanbeings because of their interest inmanipulating and con-
trolling nature. Although the complexity of the immune system
may prevent us from identifying all its internal regulatory mecha-
nisms, it is by trial-and-error experimentation that we discover if
the system can be successfully manipulated to achieve protective
immunity. Unfortunately, there is no guarantee that increasing our
knowledge of viral immunology and pathogenicity will necessarily
give us that capacity.
Philosophers of science have used the so-called convergence
argument to explain why scientists are conﬁdent that their exper-
imental ﬁndings justify a belief in the reality of the entities and
phenomena they study (Klee, 1997, p. 212). If a variety of exper-
imental results all converge on establishing what is the cause of
AIDS, then it would be perverse to follow AIDS denialists and
doubt that HIV causes AIDS. Conversely, it seems odd to believe
that the failure of hundreds of attempts to transform HIV-1 epi-
topes recognized by bnMabs into effective vaccine immunogens is
simply a remarkable coincidence which does not demand that we
modify our underlying assumptions. It certainly is more realistic
to accept that the convergence of so many negative experimental
outcomes justiﬁes the conclusion that the RV approach that has
been used is not appropriate for developing a preventive HIV-1
vaccine.
CONCLUDING REMARKS
Vaccinologists are well aware that vaccine research is an empiri-
cal science (Mascola et al., 1997) and that effective viral vaccines
have always been discovered by trial-and-error immunization tri-
als rather than by rational design using the 3D structure of viral
antigens. The reasons why successful strategies used in the past
failed in the case of HIV are well documented (Hilleman, 1992;
Kusters and Almond, 2010; Virgin and Walker, 2010; Kong and
Sattentau, 2012;Van Regenmortel, 2012). (1) The natural immune
response in HIV-1 infected individuals does not clear the infection
and there is therefore no natural immunological mechanism that
a vaccine could mimic; (2) during HIV-1 infection, antibodies
are mostly elicited against variable and accessible Env loops rather
than against functionally important but less accessible conserved
domains such as the receptor and co-receptor binding sites; (3)
HIV-1 integrates into the host genome and establishes a latent
pool of infected cells which conceal the virus from immune recog-
nition; (4) the virus progressively destroys the immune system;
(5) HIV-1 isolates exhibit an enormous antigenic variability; (6)
the immune system does not readily elicit bnAbs against cryptic
and transient HIV-1 epitopes; (7) the degree of antibody afﬁnity
maturation required to obtain antibodies that neutralize HIV-1 is
much higher than what is needed in the case of antibodies directed
to other viruses.
The present review discusses why the reductionist nature of
structure-based RV is unlikely to lead to an effective HIV vaccine.
Reductionist thinking has been prevalent in molecular biology for
half a century and still has a strong hold on investigators who aim
to develop a preventive HIV-1 vaccine. The reductionist mindset,
for instance, leads them to accept that the biological activities and
functions of Abs can be reduced to their physico-chemical struc-
tures and that the immunogenic potential of a protein molecule
can be deduced from its antigenic properties. Chemical antigenic-
ity is thereby confused with biological immunogenicity. This leads
reductionists to assume that it should be possible to control an
immune system and have it produce neutralizing antibodies sim-
ply by vaccinating an individual with a viral epitope that has
been engineered to ﬁt an nMab using structure-based design
technology. This assumption overlooks the fact that every anti-
HIV-1 bnMab is polyspeciﬁc and can bind viral epitopes different
from the one identiﬁed when the structure of the bnMab–HIV
complex was solved. There is therefore no reason why the par-
ticular HIV-1 epitope identiﬁed by crystallography should be
the one that triggered the immune response that gave rise to
the Mab.
Since the surface of a viral antigen is an antigenic continuum,
the dissection of antigens using individual Mabs tends to give a
biased view of immunological speciﬁcity and protection against
infection since these properties usually result from the collective
activities of several different antibodies reacting with the same
antigen molecule. By focusing rational vaccine design on single
epitope–paratope pairs, the neutralization synergy that tends to
occur with polyclonal antibody responses will be missed.
The structural parameters of effective HIV vaccine immuno-
gens have not been elucidated and it is therefore unfortunate that
an empirical approach to vaccine development is often denigrated
since trial-and-error experimentation remains the best strategy for
developing any vaccine.
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